Cytokine-Targeting Antibodies and Immuno-Cytokines
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (10 March 2022) | Viewed by 6372
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cytokines are key soluble mediators enabling cell–cell communication between immune cells, but also the crosstalk between our damaged tissue cells and the immune system. Several cytokines or cytokine receptors have been targeted successfully in inflammation and autoimmune diseases with classical antibodies, while the oncology field has focused on administering some naked cytokines. The field of cytokine-targeting antibodies and immuno-cytokines has experienced a growing renewed interest with the discovery and characterization of new cytokines, the introduction of engineered cytokines, multispecific antibodies, and antibody fusion proteins providing novel or redirected mechanisms of action, differentiated functions, and novel therapeutic opportunities.
This Special Issue of Antibodies aims to collect original manuscripts and reviews covering the progress in the growing field of cytokine-targeting antibodies as well as immunocytokines with potential therapeutic application in oncology, inflammation, and autoimmune or infectious diseases.
Dr. Nicolas Poirier
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cytokines
- antibody engineering
- bispecific antibodies
- antibody fusion proteins
- immuno-cytokines
- cancer immunotherapy
- inflammation
- autoimmune diseases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
